Prof Selby speaks with ecancer at the ACP immunotherapy workshop about research goals which can guide development and implementation of checkpoint immunotherapies.
He discusses the potential of oncolytic virotherapy in delivering guided therapy in mouse models, and how further research is needed to deliver the benefits in survival of best-responders to more patients within responsive diseases, and improve prospects in so-far non-responsive indications
